The positive trial results for rosnilimab in RA indicate potential future success in the market, which is a significant development for AnaptysBio. The licensing agreement with Vanda Pharmaceuticals for imsidolimab expands their portfolio, and the strong cash position ensures financial stability. These factors combined are likely to positively impact ANAB's stock price in the short term.